setmelanotide vs semaglutide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial 🚀 Breakthroughs in Health: 2026

We initially begin with a low dose of Semaglutide and gradually increases it at four-week intervals until the desired level is achieved

While couched in deliberately broad terms, the vagueness exposes a place for criticism

This research design effectively targeted patients similar to GLP-1 agonist non-responders, focusing on those who demonstrated inadequate early response to standard interventions

Since these receptors are present in various organ systems and in the brain, their roles in satiety and appetite regulation, as well as neuroinflammation and neuroplasticity, must be considered

Promoterless gene targeting without nucleases ameliorated hemophilia B in mice

Key takeaways People with Type 2 diabetes who need to control their blood glucose and lose weight may benefit from taking metformin and Wegovy together